SAR447537

DRUG2 trials

Sponsors

Sanofi

Conditions

Alpha 1-Antitrypsin DeficiencyEmphysema

Phase 2

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

CompletedNCT05856331

SanofiAlpha 1-Antitrypsin Deficiency, Emphysema

Start: 2023-10-12End: 2025-08-06Updated: 2025-08-11

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Active, not recruitingNCT05897424

SanofiAlpha 1-Antitrypsin Deficiency, Emphysema

Start: 2024-06-20End: 2028-09-30Target: 185Updated: 2026-04-13